{"groups":[{"description":"Cycle 1: Cyclophosphamide 300 mg/m\\^2 intravenous (IV) twice a day on Days 1-3. Mesna 600 mg/m\\^2 continuous IV Days 1-3. Doxil 25 mg/m\\^2 IV over 1 hour on Day 2. Vincristine 1.4 mg/m\\^2 IV on Days 4 and 11. Dexamethasone 40 mg Iv or oral on Days 1 - 4 and 11 - 14.\n\nCycle 2: Methotrexate 200 mg/m\\^2 over 2 hours on Day 1 and 800 mg/m\\^2 over 22 hours on day 1. Cytarabine 3 Gm/m\\^2 IV twice a day on Days 2 and 3.","id":"FG000","title":"HCVIDDOXIL Regimen"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Non-Compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Congestive Heart Failure"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Transplant in CR"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Unrelated Infection/Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"53"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the 55 participants registered, two participants were found not to be eligible prior to start of study therefore are excluded from trial details.","recruitmentDetails":"Recruitment period: September 17, 2003 to May 8, 2009. All recruitment done at The University of Texas MD Anderson Cancer Center."}